Morgan Stanley raised the firm’s price target on Phibro Animal Health (PAHC) to $49 from $45 and keeps an Equal Weight rating on the shares. Phibro’s latest print reflects solid execution, particularly around its Zoetis MFA transaction/Animal Health segment/cost management, with a Q2 beat, raised FY26 guidance, and notable margin expansion, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PAHC:
- Phibro Animal Health reports Q2 adjusted EPS 87c, consensus 67c
- Phibro Animal Health raises FY26 EPS view to $2.93-$3.10 from $2.64-$2.81
- Phibro Animal Health Declares Quarterly Cash Dividend
- PAHC Earnings this Week: How Will it Perform?
- Phibro Animal Health Announces Generational CEO Succession Plan